These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 18176601

  • 1. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.
    Roses RE, Xu M, Koski GK, Czerniecki BJ.
    Oncogene; 2008 Jan 07; 27(2):200-7. PubMed ID: 18176601
    [Abstract] [Full Text] [Related]

  • 2. Direct and indirect role of Toll-like receptors in T cell mediated immunity.
    Xu D, Liu H, Komai-Koma M.
    Cell Mol Immunol; 2004 Aug 07; 1(4):239-46. PubMed ID: 16225766
    [Abstract] [Full Text] [Related]

  • 3. TLR signaling by tumor and immune cells: a double-edged sword.
    Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H.
    Oncogene; 2008 Jan 07; 27(2):218-24. PubMed ID: 18176603
    [Abstract] [Full Text] [Related]

  • 4. Regulatory T cells and Toll-like receptors in tumor immunity.
    Wang RF, Peng G, Wang HY.
    Semin Immunol; 2006 Apr 07; 18(2):136-42. PubMed ID: 16469504
    [Abstract] [Full Text] [Related]

  • 5. Toll-like receptors and immune regulation: implications for cancer therapy.
    Wang RF, Miyahara Y, Wang HY.
    Oncogene; 2008 Jan 07; 27(2):181-9. PubMed ID: 18176599
    [Abstract] [Full Text] [Related]

  • 6. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.
    Roses RE, Datta J, Czerniecki BJ.
    Radiat Res; 2014 Aug 07; 182(2):211-8. PubMed ID: 24992163
    [Abstract] [Full Text] [Related]

  • 7. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H, Marshall NA, Mills KH.
    Oncogene; 2008 Jan 07; 27(2):168-80. PubMed ID: 18176598
    [Abstract] [Full Text] [Related]

  • 8. Toll-like receptors' two-edged sword: when immunity meets apoptosis.
    Salaun B, Romero P, Lebecque S.
    Eur J Immunol; 2007 Dec 07; 37(12):3311-8. PubMed ID: 18034428
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic targeting of pattern-recognition receptors.
    Rezaei N.
    Int Immunopharmacol; 2006 Jun 07; 6(6):863-9. PubMed ID: 16644471
    [Abstract] [Full Text] [Related]

  • 10. Innate immunity and cancer therapy.
    Maruyama K, Selmani Z, Ishii H, Yamaguchi K.
    Int Immunopharmacol; 2011 Mar 07; 11(3):350-7. PubMed ID: 20955832
    [Abstract] [Full Text] [Related]

  • 11. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B, Navabi H, Adams M.
    Vaccine; 2009 May 26; 27(25-26):3401-4. PubMed ID: 19200817
    [Abstract] [Full Text] [Related]

  • 12. Combining innate immunity with radiation therapy for cancer treatment.
    Koski GK, Czerniecki BJ.
    Clin Cancer Res; 2005 Jan 01; 11(1):7-11. PubMed ID: 15671522
    [No Abstract] [Full Text] [Related]

  • 13. Regulation of TLR expression, a new perspective for the role of VIP in immunity.
    Gomariz RP, Arranz A, Juarranz Y, Gutierrez-Cañas I, Garcia-Gomez M, Leceta J, Martínez C.
    Peptides; 2007 Sep 01; 28(9):1825-32. PubMed ID: 17706836
    [Abstract] [Full Text] [Related]

  • 14. Toll-like receptors, inflammation and cancer.
    Tsan MF.
    Semin Cancer Biol; 2006 Feb 01; 16(1):32-7. PubMed ID: 16153858
    [Abstract] [Full Text] [Related]

  • 15. Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor signaling network.
    Chinenov Y, Rogatsky I.
    Mol Cell Endocrinol; 2007 Sep 15; 275(1-2):30-42. PubMed ID: 17576036
    [Abstract] [Full Text] [Related]

  • 16. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS, Quezada SA, Allison JP.
    Immunol Rev; 2008 Aug 15; 224():141-65. PubMed ID: 18759925
    [Abstract] [Full Text] [Related]

  • 17. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
    Wang RF.
    Hum Immunol; 2008 Nov 15; 69(11):811-4. PubMed ID: 18817828
    [Abstract] [Full Text] [Related]

  • 18. Toll-like receptors and innate immunity.
    Kumar H, Kawai T, Akira S.
    Biochem Biophys Res Commun; 2009 Oct 30; 388(4):621-5. PubMed ID: 19686699
    [Abstract] [Full Text] [Related]

  • 19. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A, Abdelnoor AM.
    Immunopharmacol Immunotoxicol; 2009 Oct 30; 31(3):331-8. PubMed ID: 19555209
    [Abstract] [Full Text] [Related]

  • 20. Regulatory T cells and toll-like receptors in cancer therapy.
    Wang RF.
    Cancer Res; 2006 May 15; 66(10):4987-90. PubMed ID: 16707417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.